Results 71 to 80 of about 9,104 (252)

Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects

British Journal of Clinical Pharmacology, EarlyView.
Aims Oral administration of (S)‐ketamine for treatment‐resistant depression (TRD), as alternative to the registered intranasal or off‐label intravenous administrations, has high potential. However, it is characterized by an extensive first‐pass metabolism, resulting in low (S)‐ketamine exposure and high levels of active metabolites, including (S ...
Marije E. Otto, Gabriël E. Jacobs, Joost C. van Mechelen, Laura G. J. M. Borghans, Johan G. C. van Hasselt, Linda B. S. Aulin   +5 more
wiley   +1 more source

Risk of injury associated with the sedative potential of second‐generation antihistamines: A nationwide retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Individual second‐generation antihistamines may possess differential sedative potential due to the variability in central histamine receptor H1 occupancy. This study aimed to evaluate whether the sedative potential of second‐generation antihistamines is associated with the risk of injury during Japan's pollen season. Methods We conducted a
Jumpei Taniguchi, Shotaro Aso, So Sato, Hideo Yasunaga   +3 more
wiley   +1 more source

Safety concerns reported by coroners following fentanyl patch fatalities in England, Wales and Northern Ireland between 1997 and 2024

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim To identify safety concerns reported by coroners following fentanyl patch‐related deaths in England, Wales and Northern Ireland, and determine differences in coronial reporting. Methods A systematic case series linking the National Programme on Substance Use Mortality (NPSUM) and the Preventable Deaths Tracker (PDT) (https ...
Eman Mshari, Caroline S. Copeland, Georgia C. Richards   +2 more
wiley   +1 more source

Piloting the UK’s First Home-Office-Licensed Pharmacist-Led Drug Checking Service at a Community Substance Misuse Service

Behavioral Sciences, 2020
(1) Introduction: Drug-related deaths in the UK are at concerning high levels. The unknown content and purity of illicit substances can cause unpredictable adverse effects and thus a public health risk with no sign of abating.
Amira Guirguis, Rosalind Gittins, Fabrizio Schifano   +2 more
doaj   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

British Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou, Dasha Nicholls, David J. Nutt, Martina Di Simplicio   +3 more
wiley   +1 more source

Diffusion of Carbamazepine in Hydrophobic Zeolites: A Comparative Study Using Classical and Machine‐Learned Potentials

Chemistry – A European Journal, EarlyView.
Can hydrophobic, shape‐selective zeolites efficiently remove the persistent pharmaceutical CBZ from water? This work moves beyond the static picture of interaction energies by modeling diffusion with umbrella sampling and machine‐learned potentials. Even high intrinsic diffusion barriers can be overcome through exergonic adsorption from water, yielding
Jakob Brauer, Richard Kendra, Carlos Bornes, Lukáš Grajciar, Michael Fischer   +4 more
wiley   +1 more source

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

Clinical Pharmacology &Therapeutics, EarlyView.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le, Sabrina Wong, Danica E. Johnson, Diana K. Orsini, Yang Jing Zheng, Kayla M. Teopiz, Christine E. Dri, Joshua D. Rosenblat, Roger S. McIntyre   +8 more
wiley   +1 more source

Focus on ‘Psychiatry and Addiction: A Multi-Faceted Issue’

Brain Sciences
The reconceptualization of addiction as a neurobiological disease has gained significant traction over recent decades, informed by advances in neuropharmacological and neuroimaging research [...]
Fabrizio Schifano, Giovanni Martinotti, Norbert Scherbaum   +2 more
doaj   +1 more source

A Novel Workflow for Fast Elucidation of Drug Metabolites for Screening—Combining In Silico Metabolite Prediction With Trapped Ion Mobility QTOF‐MS

Drug Testing and Analysis, EarlyView.
UHPLC‐timsTOF‐MS with in silico prediction and automated annotation enabled rapid identification of quetiapine metabolites from pHLMs, facilitating their inclusion in targeted LC‐QTOF‐MS urine screening and improving biomarker detection for toxicological applications.
Annette Zschiesche, Birgit Schneider, Ilona Nordhorn, Carsten Baessmann, Laura M. Huppertz, Jürgen Kempf   +5 more
wiley   +1 more source

Semaglutide as a Possible Calmodulin Binder: Ligand-Based Computational Analyses and Relevance to Its Associated Reward and Appetitive Behaviour Actions

Scientia Pharmaceutica
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has gained considerable attention as a therapeutic agent for type 2 diabetes mellitus and obesity.
Giuseppe Floresta, Davide Arillotta, Valeria Catalani, Gabriele Duccio Papanti Pelletier, John Martin Corkery, Amira Guirguis, Fabrizio Schifano   +6 more
doaj   +1 more source